Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1926-1935

  Milenic, Diane E ^a,c   Garmestani, Kayhan ^a   Brady, Erik D ^a   Albert, Paul S ^a   Abdulla, Alia ^a   Flynn, Joseph ^b   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MONOCLONAL ANTIBODY; TRASTUZUMAB PB 212; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; LEAD; RADIOSENSITIZING AGENT; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUDE MOUSE; PERITONEAL DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; SURVIVAL; SURVIVAL TIME; XENOGRAFT; ANIMAL; CARCINOMA; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; EVALUATION; FEMALE; IMMUNOLOGY; LINEAR ENERGY TRANSFER; METASTASIS; METHODOLOGY; MORTALITY; PERITONEUM TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; DEOXYCYTIDINE; FEMALE; HUMANS; LEAD RADIOISOTOPES; LINEAR ENERGY TRANSFER; MICE; MICE, NUDE; PERITONEAL NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250217093     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2300     Document Type: Article

References (62)

1. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490-7.
2. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988;80:449-52.
3. Milenic D, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41.
4. Milenic DE, Garmestani K, Brady ED, etal. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557-68.
5. Agus DB, Bunn PA, Jr., Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000;27:53-63.
6. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61.
7. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
8. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335-40.
9. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-22.
10. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol 2005;1:7-17.
11. Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′- difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 1997;3:777-82.
12. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24-S7-8.
13. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
14. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-23.
15. Shewach DS, Ellero J, Mancini WR, Ensminger WD. Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 1992;43:1579-85.
16. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005;10:34-51.
17. Pauwels B, Korst AE, Lambrechts HA, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 2006;58:219-28.
18. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226-34.
19. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002;95:933-40.
20. Gregoire V, Hittelman WN, Rosier JF, Milas L. Chemoradiotherapy: radiosensitizing nucleoside analogues [review]. Oncol Rep 1999;6:949-57.
21. Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929-37S.
22. 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004;109:618-26.
23. Cividalli A, Livdi E, Ceciarelli F, et al. Combined use of gemcitabine and radiation in mice. Anticancer Res 2001;21:307-12.
24. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 2002;97:386-92.
25. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 2004;64:1460-7.
26. Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro 1976;12:180-91.
27. 212Pb. Nucl Med Biol 2000;27:93-100.
28. Chappell LL, Ma D, Milenic DE, et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴-tetraacetic acid for radiolabeling proteins. Nucl Med Biol 2003;30:581-95.
29. 111In labeled Herceptin. Nucl Med Biol 2002;29:599-606.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
31. Dadachova E, Chappell LL, Brechbiel MW. Spectro-photometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977-82.
32. Xu F, Yu Y, Le XF, et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 1999;5:3653-60.
33. Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res 1999;5:3048-55s.
34. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 1996;23:65-71.
35. De Santes K, Slamon D, Anderson SK, et al. Radio-labeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916-23.
36. Tsai SW, Sun Y, Williams LE, et al. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327-34.
37. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488-99.
38. Soyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alphaparticle traversals of individual cells. Int J Radiat Biol 2000;76:1315-22.
39. Milenic DE, Brechbiel MW. Targeting of radioisotopes for cancer therapy. Cancer Biol Ther 2004;3:361-70.
40. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev 2001;101:2019-36.
41. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 2002;100:208-16.
42. 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional a-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804-8.
43. Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990;50:4221-6.
44. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
45. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. JNucl Med 1997;38:1944-50.
46. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-46.
47. 224Ra. Appl Radiat Isot 1988;39:283-6.
48. Hamacher KA, Sgouros G. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters. Med Phys 2001;28:1857-74.
49. Rogers BE, Roberson PL, Shen S, etal. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 2005;20:502-13.
50. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
51. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol 2005;15:245-53.
52. Toma S, Colucci L, Scarabelli L, et al. Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. JCell Physiol 2002;193:37-41.
53. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
54. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003;30:22-6.
55. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
56. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6 Suppl 6:7-13.
57. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
58. Wachters FM, van Putten JW, Maring JG, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-62.
59. Rosier JF, Michaux L, Ameye G, et al. The radioenhancement of two human head and neck squamous cell carcinomas by 2′-2′ difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs. Mutat Res 2003;527:15-26.
60. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 2000;60:6080-8.
61. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 2001;7:3186-92.
62. Woloschak GE, Chang-Liu CM, Jones PS, Jones CA. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res 1990;50:339-44.